Radiofrequency ablation of lung tumours by Bargellini, Irene et al.
Abstract Pulmonary radiofrequency ablation (RFA) has
become an increasingly adopted treatment option for
primary and metastatic lung tumours. It is mainly per-
formed in patients with unresectable or medically inoper-
able lung neoplasms. The immediate technical success rate
is over 95%, with a low periprocedural mortality rate and
8–12% major complication rate. Pneumothorax represents
the most frequent complication, but requires a chest tube
drain in less than 10% of cases. Sustained complete tumour
response has been reported in 85–90% of target lesions.
Lesion size represents the most important risk factor for
local recurrence. Survival data are still scarce, but initial
results are very promising. In patients with stage I non-
small-cell lung cancer, 1- and 2-year survival rates are
within the ranges of 78–95% and 57–84%, respectively,
with corresponding cancer-specific survival rates of 92%
and 73%. In selected cases, the combination of RFA and
radiotherapy could improve these results. In patients with
colorectal lung metastasis, initial studies have reported
survival data that compare favourably with the results of
metastasectomy, with up to a 45% 5-year survival rate.
Further studies are needed to understand the potential role
of RFA as a palliative treatment in more advanced disease





Radiofrequency ablation (RFA) is nowadays the most
widely used ablative treatment, and it is considered the
treatment of choice in the liver for inoperable patients with
early primary or secondary neoplastic disease [1].
In the lung, initial experiments in animal models have
demonstrated that RFA can destroy a controlled area of both
healthy pulmonary tissue and experimentally induced lung
malignancy [2, 3]. A given quantity of RF current delivered
into the lung produces a larger volume than in subcutane-
ous tissues or in the kidney, probably as a result of heat
insulation and low electric conductivity provided by the
lung surrounding the tumour.
Since the advent of these initial experimental models, the
interest in this treatment technique has increased worldwide
and, today, lung RFA has become established in selected
patients in many institutions, providing high local tumour
control rates [4–7].
This article provides an overview of the current status of
lung RFA in terms of indications, technique, complications
and results.
Indications
Currently, RFA is indicated in patients with primary or
secondary lung tumours (in particular, from colorectal
cancer) that are considered inoperable, either for
medical conditions or for unfavourable tumour location
[8, 9].
Patient selection for RFA should be carefully performed
by a multidisciplinary team [9]. Preprocedural clinical and
imaging workup is required to assess indications, stage the
tumour, exclude contraindications (such as uncorrected
I. Bargellini (*):E. Bozzi:R. Cioni: B. Parentini:
C. Bartolozzi






Radiofrequency ablation of lung tumours
Irene Bargellini & Elena Bozzi & Roberto Cioni &
Barbara Parentini & Carlo Bartolozzi
Received: 11 October 2010 /Revised: 17 March 2011 /Accepted: 8 June 2011 /Published online: 20 July 2011
# European Society of Radiology 2011
Insights Imaging (2011) 2:567–576
DOI 10.1007/s13244-011-0110-7coagulopathy) and plan the treatment, with particular
reference to the needle trajectory.
Biopsy is required in patients suspected of having
primary lung cancer or in patients with lung metastasis
with atypical imaging appearances. Biopsy should general-
ly be performed before RFA, unless the patient is
considered to be at very high risk, in which case biopsy
and RFA could be performed in one setting.
Non-small-cell lung cancer
Standard of care for stage I non-small-cell lung cancer
(NSCLC) is represented by surgical resection. However,
only about one-third of patients are eligible for surgical
intervention.
Sublobar resections may represent an alternative to
lobectomy in patients with limited cardiopulmonary re-
serve, thanks to technical improvements that have increased
local tumour control and survival rates [10].
Conventional radiotherapy, stereotactic body radiothera-
py and RFA can also be offered to medically inoperable
stage I NSCLC patients. A recent retrospective non-
randomised study carried reported comparable survival
rates after sublobar resection, RFA or percutaneous cryoa-
blation in a series of 64 patients who were deemed not to be
candidates for lobectomy [10]. Thus, percutaneous ablative
treatments can represent valid minimally invasive alter-
natives in inoperable patients.
Radiofrequency ablation can also be a reasonable option
at more advanced stages of the disease, such stages III and
IV , in the presence of a satellite nodule in the same lobe or
in a different ipsilateral or contralateral lobe. Moreover,
RFA can be offered in stage III or IV patients who have a
persistent solitary nodule after radiation or chemotherapy.
Finally, RFA represents a valid option in recurrent isolated
lesions after lung resection [8], keeping in mind that
percutaneous treatments in patients who have undergone
previous lobectomy may be associated with higher inci-
dence of periprocedural complications.
In a curative intent, indications for RFA are strictly
dependent on anatomical criteria, such as nodule size and
location. In fact, lesions larger than 5 cm should be excluded
from RFA, whereas lesions from 3 to 5 cm should be
considered with caution because of the high incidence of
recurrence [11]. Moreover, nodules located less than 1 cm
from the trachea, main bronchi, oesophagus and central
vessels should be excluded, as they are considered at high
risk of complications and can often not be completely ablated.
Lung metastases
Lung is the second most frequent site of metastases. RFA has
become a reasonable treatment option in non-surgical patients
withlimitedpulmonarymetastaticinvolvement,particularlyfor
colorectal cancer [8]. It is generally accepted that RFA should
be performed in the presence of less than five lesions per
hemithorax. However, this does not represent an absolute
criterion, as long as all the lesions can be successfully ablated.
Percutaneous ablation is also an interesting minimally
invasive option in patients with recurrent disease after a
previous resection.
As for primary lung tumours, tumour size (<5 cm,
ideally <3.5 cm) and location (>1 cm trachea, main bronchi,
oesophagus, central vessels) are important determinants for
RFA.
Procedure
The RF is a sinusoidal current with a frequency of 400 to
500 kHz that heats tissues through ionic agitation. It
induces a thermal destruction of tissues by heating cells to
>60°C obtaining a non-reversible cellular modification,
called “coagulative necrosis” [12]. The goal of ablative
techniques is to obtain and maintain a temperature from 50°
C to 100°C through the target volume by the percutaneous
insertion of a needle.
In the specific setting of pulmonary ablation, the intrinsic
characteristics of lungtissue interfere with the energy delivery
more than in other tissues, e.g. liver. For this reason, different
methods have been developed to improve the energy-tissue
interaction, to increase the RFAvolume by a single delivery
and, ultimately, to treat larger lesions. Initially, the single-
needle electrode was implemented by the simultaneous
application of multiple probes; nevertheless, the precise
positioning of more than two electrodes was technically
complex. Thus, expandable, cooled and bipolar needles have
been introduced for treating lung lesions.
Expandable needles are the most commonly used
devices in lung RFA. They contain several (8–12) electro-
des that are deployed into the target tissue in a single
insertion. Each electrode produces a small area of ablation;
the summation of all the areas determines the destruction of
a larger portion of tumour. The number of deployable
electrodes and the degree of deployment can vary according
to the desired volume of ablation.
The cooled-tip electrode consists of a double-lumen
needle in which the electrode is cooled with chilled water.
This technique increases the current delivered, without
boiling the tissue close to the needle, where the current
density is very high.
Finally, the micro-perfused electrodes take advantage of
enhanced RF delivery with the help of saline perfusion. The
administration of fluid solution into the tissue during the
thermal ablation increases the electrical conductivity,
obtaining larger ablation volumes in shorter times [13].
568 Insights Imaging (2011) 2:567–576In RFA, the patient is part of a closed-loop circuit.
Therefore, any electrode requires the placement of disper-
sive electrodes (ground pads) on the patient’s thighs.
Lung RFA has to be performed under anaesthesiological
care. There is no consensus in the literature regarding the best
anaesthesiological technique during RFA, taking into account
that most selected patients carry a medium to high anaesthesi-
ology risk. Choice of sedation may depend on the patient’s
status and tumour treated; thus, different techniques should be
taken into consideration. Hoffmann et al. reported similar
results, in terms of feasibility, complication rate, hospitalisation
and local tumour control, aftergeneral anaesthesia or conscious
sedation, and concluded that conscious sedation should be
preferred, reserving general anaesthesia for non-compliant
patients [14]. However, other authors reported lower feasibil-
ity rates and higher periprocedural pain after conscious
sedation compared with general anaesthesia [15, 16].
Computed tomography is currently the only accurate
imaging technique for guidance during lung RFA. The
correct planning of the needle track is a key factor for
technical success. The path should be the shortest possible,
and it should avoid interlobar fissures, bullae and vessels.
Multiplanar reconstructions before current delivery are
mandatory to assess adequate electrode positioning relative
to tumour margins in all planes (Fig. 1).
Radiofrequency delivery has to be adapted to the tumour
location, which can cause variation in impedance. In fact,
the tumour surrounded by lung parenchyma is electrically
and thermally insulated by the air-filled lung compared with
the tumour abutting the pleura, which requires more energy
deposition [17]. Moreover, subpleural tumours can be
difficult to puncture; an artificially induced pneumothorax
has been proposed as a means of separating the subpleural
tumour from the pleura or the mediastinum [18].
After probe removal, a CT is required to exclude
immediate complications, such as pneumothorax, and to
estimate the area of ablation. The presence of an area of
ground-glass opacity around the tumour margins is reported
to be indicative of adequate tumour ablation with safety
ablation margins (Fig. 2)[ 19].
Complications
Radiofrequency ablation of lung tumours is a relatively safe
procedure, with low mortality (around 0.4%) and excellent
tolerance in terms of respiratory function, although the reported
periprocedural morbidity rate ranges from 15.5% to 55.6%
(median 35.7%), with an 8–12% major complication rate [20].
Complications can be classified depending on their
severity, according to the SIR grading system on a per-
session basis [21]. Moreover, they can be divided into
periprocedural and postprocedural complications.
The most common periprocedural complication is
pneumothorax, occurring in up to 60% of ablation
sessions. Most cases of pneumothorax do not require
any treatment, whereas in about 20% of procedures
pneumothorax can be solved immediately after RFA by
insertion of a small needle catheter. Only about 4% to
12% of procedures require chest tube drainage (Fig. 3)
[17]. Reported risk factors for the development of
pneumothorax are previous pulmonary surgery (although
this result has not been confirmed in all studies),
emphysema, the increased length of the aerated lung
traversed by the electrode, the mean number of ablated
tumours and the number of electrode positioning [22–24].
Intractable pneumothorax due to bronchopleural fistula
has been reported in about 0.6% of cases [25].
Small reactive pleural effusions are commonly found,
usually resolving spontaneously, whereas pleural effusion
requiring chest tube drainage is a rare event.
Similarly, parenchyma haemorrhage can occur in approx-
imately 8–10% of ablations and tends to solve spontaneously
Fig. 1 Primary lung tumour located in the right lower lobe and treated
by RFA. The axial CTshows adequate positioning of the needle within
the nodule. Multiplanar reformations demonstrate that the needle is
not correctly positioned in the centre of the nodule (B,C)
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limiting hemoptysis can occur, whereas more severe haemor-
rhage is a rare event that can occur in tumours in contact
with the hilum. Delayed major haemorrhage has also been
reported, caused by the development of false aneurysms of
the pulmonary artery and requiring coil embolisation [26].
Other reported complications are subcutaneous emphy-
sema, infection and pulmonary abscesses (Fig. 5).
Tumour seeding along the needle tract is a very rare
complication. Although unproven, track ablation at the end
of the procedure is recommended to reduce the risk of
seeding [27].
Fig. 2 P r i m a r yl u n gt u m o u r
located in the right lower lobe
(A). The CTcontrol performed
immediately after RFA shows a
large area of ground glass sur-
rounding the nodule (B); the
needle was slightly to the right
of centre of the nodule
Fig. 3 Subpleural primary lung
tumour in the right lower lobe
(A). The CTcontrol during RFA
demonstrates correct placement
of the needle with a minimal
area of pneumothorax (B). The
CTcontrol performed at the end
of the procedure shows a large
pneumothorax (C) that required
chest tube drainage (D)
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associated with a number of side effects. Mild to moderate
periprocedural and postprocedural pain are frequently
reported, lasting up to 7 days and requiring oral analgesics,
to prevent dyspnoea. Also, raised body temperature (up to
38°C) is common in the periprocedural period.
Imaging follow-up and tumour response
Target tumour response is most frequently assessed by
computed tomography (CT).
As the aim of RFA is to produce a volume of coagulative
necrosis larger than the native nodule, CT performed in the
first month after the procedure should demonstrate a hyper-
attenuating area larger than the treated nodule.
The ablation zone should then progressively shrink as
early as 2 to 3 weeks after treatment (Fig. 6)[ 17].
Cavitation of the ablation zone has been described in up to
30% of ablations and seems to occur more frequently when the
lesion is in contact with a segmental bronchus (Fig. 6)[ 28].
Follow-up usually includes contrast-enhanced CT of the
lung 1 month after the procedure and every 3 months
thereafter. Recurrences can occur as long as 2 years after
treatment; thus, continued imaging follow-up is needed [11].
Up to now, no universal agreement has been reached
regarding the most proper criteria to assess tumour response
after lung RFA.
Fig. 4 Primary lung tumour in the right upper lobe (A). The CT
control during RFA demonstrates correct placement of the needle with
a limited area of parenchymal haemorrhage (B). The CT control
performed at the end of the procedure shows pleural effusion and a
consolidation corresponding to parenchyma haemorrhage (C) without
haemoptysis. No adjunctive procedures were required and the CT
controls performed 3 (D) and 6 months (E) after treatment
documented progressive reduction of the consolidation and shrinkage
of the tumour nodule
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should not increase in size on subsequent imaging.
However, relying exclusively on tumour size implies a late
discovery of incomplete treatment and local recurrence [5,
11].
Amended RECISTcriteria have therefore been proposed,
taking into account not only the lesion size, but also tumour
geometry and contrast enhancement. In a large multicenter
trial, complete response was defined as a decrease in the
longest diameter of at least 30% compared with the
diameter measured at the 1-month CT examination, with
no evidence of peripheral tumour growth and no evidence
of contrast enhancement [7]. Also, cyst and cavity
formation have been regarded as indicative of complete
response (Fig. 6)[ 8].
Nonetheless, the tumour enhancement after lung RFA
seems to be less informative than for other tumours, such as
hepatocellular carcinoma. In a recent pilot experimental
study, diffusion MRI has demonstrated promising results in
identifying complete tumour response [29]; nonetheless,
these results need further confirmation and the usefulness of
this imaging technique is limited in the case of small
pulmonary nodules.
To avoid the late diagnosis of incomplete ablation, PET-
CT has been proposed in some centres [8, 17, 30, 31],
providing higher sensitivity and specificity than CT in
depicting residual viable tumour. Okuma et al. demonstrat-
ed that the timing of PETafter RFA is a key factor. In fact,
fluorine-18 fluorodeoxyglucose uptake is highly increased
1 to 3 weeks after ablation, because of the post-treatment
inflammatory reaction, and, therefore, at least a 4-week
interval is required to avoid false-positive results [30, 31].
However, the use of PET in post-RFA follow-up is still
limited in clinical practice.
The lack of universally adopted criteria to assess tumour
response could explain the heterogeneity of published
results in terms local tumour control rate, which ranges
from 38% to 97%, with a median reported rate of complete
ablation of 90% [32].
In a recently published series of 91 patients with NSCLC
treated by RFA followed for 1–72 months, tumour recurrence
was observed in 43% of patients, and the most common
pattern of recurrence was local [11], suggesting the need for
more aggressive initial ablation treatment and underlining the
potential role of adjuvant radiation as a means of improving
local tumour control, particularly in larger tumours [33, 34].
Negative predictive factors of complete tumour ablation
are tumour size larger than 3 cm and contact with large
vessels [5, 7, 35–37].
Survival
Survival data after lung RFA are still scarce, with few series
providing survival beyond 3 years. Moreover, there are no
prospective randomised studies comparing RFA with sur-
gery, other ablative treatments or radiotherapy.
Non-small-cell lung cancer
Initial investigations report promising outcomes in patients
with stage I NSCLC, with 1- and 2-year survival rates in
the range of 78–95% and 57–84% respectively [4, 6, 7, 16,
36, 38], and about 36% 3-year survival [6]. These data are
encouraging and compare favourably with the results
provided by conventional radiation therapy.
In a series of 75 primary NSCLC patients, Simon et al.
reported median overall survival periods of 30 months at
Fig. 5 Subpleural lung tumour treated by RFA (A). The CT control
performed 9 months after treatment depicted a subcutaneous mass
adjacent to the tumour with peripheral enhancement and air bubbles.
Under suspicion of a secondary location (tumour seeding), biopsy was
performed (C), allowing the final diagnosis of an abscess formation
involving the treated lesion with extension to the thoracic wall
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significantly related to tumour size, with almost 50% 5-
year survival for tumours ≤3c m[ 6]. This study did not
report cancer-specific survival; thus, the effect of RFA itself
was not specifically determined.
Conversely, the RAPTURE trial (the only prospective
multicenter trial published to date) reported a striking
difference between overall survival (70% and 48% at 1 and
2 years, respectively) and cancer-specific survival (92% and
73% at 1 and 2 years respectively), reflecting the role of
comorbidities and poor pulmonary function in these patients
who are selected for RFA after exclusion from surgery [7].
F o rl a r g e rt u m o u r s ,t h ec o m b i n a t i o no fR F Aa n d
radiotherapy could improve the results. In a series of 41
patients, Grieco et al. reported a 57% 3-year survival rate
[33], which represents an encouraging outcome.
Colorectal lung metastases
As for primary lung cancer, survival data after RFA of
colorectal lung metastasis are encouraging, with survival rates
of54–78% and46–57%at2and3yearsrespectively[6, 7, 39].
Longer follow-up data have been recently published,
reporting 5-year survival rates of 35–45% [40–42]. These
results compare favourably with the 48% 5-year survival
rate reported after metastasectomy in a systematic review of
1,684 patients [43]. Predictive factors for survival after RFA
are similar to those described after metastasectomy.
Fig. 6 Non-small-cell lung car-
cinoma (NSCLC) located in the
right lower lobe, adjacent to a
segmental bronchus (A). RFA
was successfully performed (B).
The 1-month CTcontrol dem-
onstrated a large area of cavita-
tion including the entire nodule,
with no significant contrast en-
hancement (C,D); the findings
were considered indicative of
complete response. The 6- and
12-month CTexaminations (E,
F) demonstrated the progressive
reduction in size of the cavita-
tion with formation of a fibrotic
band, corresponding to a com-
plete response to treatment
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diameter less than 3 cm, single-lung metastasis, lack of
extrapulmonary metastasis and normal carcinoembryonic
antigen (CEA) level are all positive prognostic factors for
survival after RFA. In patients with no extrapulmonary
metastases the 5-year survival rate was 57% and when both
tumour size less than 3 cm and disease limited to the lung
were present, the 3-year survival reached 78%. Moreover,
in patients with negative CEA levels survival at 5 years was
62.5%.
Survival also seems to be influenced by the tumour
response to RFA and by the association with systemic
chemotherapy [42].
According to these data, in the setting of colorectal
metastases, it is reasonable to compare RFA with
metastasectomy.
Conclusions
In less than a decade, pulmonary RFA has become a highly
appealing, minimally invasive treatment option that has
been widely adopted in several centres to treat primary and
secondary lung tumours.
In experienced hands, it is a safe technique with high
local tumour control rates.
Indeed, according to the latest NICE (National Institute
for Health and Clinical Excellence) guidelines [9], “the
current evidence on the efficacy of percutaneous radio-
frequency ablation (RFA) for primary or secondary lung
cancers is adequate in terms of tumour control and safety;
thus, the procedure should be considered in patients with
small, early-stage lung cancers or small numbers of lung
metastases who are unsuitable for, or prefer not to undergo,
surgery”.
In patients with primary NSCLC, surgery should remain
the standard therapy. However, RFA is becoming a valid
tool in specific clinical scenarios as a single treatment as
well as in combination with other treatments, such as
radiotherapy.
In the setting of colorectal lung metastases, RFA is
associated with relatively high mid- and long-term survival
rates, which are far better than those obtained with any
chemotherapy regimen. Thus, it would be reasonable to
compare the results of RFA with the outcomes of surgical
resection.
There are several ongoing prospective trials that will
further assess the long-term results of RFA in lung tumours
[44]. Prospective randomised trials would also be desirable.
For instance, there is a need to compare RFA with
stereotactic radiation therapy. The latter has been proven
to be associated with high local tumour control rates (up to
80% for secondary lesions and over 90% for stage I
NSCLC) and encouraging survival rates [45–47] and is
being proposed as a valid alternative to surgery in selected
patients.
Finally, the role of RFA as a palliative treatment in larger
tumours or in more advanced disease deserves further
investigation.
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